Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 23Recruiting 13Not yet recruiting 7Active not recruiting 6Withdrawn 3Unknown 3Terminated 2Enrolling by invitation 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1

Conditions

Sarcoma, Ewing 1Neoplasm Metastasis 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Interventional × PM 01183 × Clear all
NCT06385548 2025-04-01

LiDer

Vall d'Hebron Institute of Oncology

Phase 1/2 Withdrawn
Gynecologic

Endometrial Neoplasms

NCT05574504 2024-08-01

Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

AdventHealth

Phase 2 Withdrawn
Genitourinary

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT05042934 2022-02-10

Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Sarcoma

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡